| Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
|
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation |
|
Haematologica |
Aplastic Anemia |
| Germline variants in acquired aplastic anemia: current knowledge and future perspectives |
|
Haematologica |
Aplastic Anemia |
| Is blood transfusion safe during the COVID-19 pandemic? |
|
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
| Targeting the Microenvironment in MDS: The Final Frontier |
|
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
